LEVI & KORSINSKY, LLP: PHASE III CLINICAL TRIAL DESIGN AND ENDPOINT SELECTION AT CENTER OF ULTRAGENYX PHARMACEUTICAL SECURITIES LITIGATION
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: GlobeNewswire
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between August 3, 2023 and December 26, 2025. Click here to learn more about this case You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. The Alleged Phase III Study Design Methodology Rare disease drug development presents unique challenges in clinical trial design. For osteogenesis imperfecta ("OI"), a genetic bone disorder characterized by fragile bones, measuring treatment efficacy requires careful attention to patient selection, control group composition, and endpoint variability. The lawsuit alleges that management's repeated expressions of confidence in the Phase III Orbit and Cosmic studies' ability to demonstrate reduced annualized fracture rates ("AFR") were misleading given inherent study design limitations
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlinePR Newswire
- RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026PR Newswire
- Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RAREPR Newswire
- RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud LawsuitPR Newswire
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RAREGlobeNewswire
RARE
Earnings
- 2/12/26 - Miss
RARE
Sec Filings
- 2/23/26 - Form 8-K
- 2/18/26 - Form 10-K
- 2/12/26 - Form 8-K
- RARE's page on the SEC website